ADA Updates on Finerenone, SGLT2 Inhibitors, and Race-Based

ADA has made an interim change to its latest Standards of Medical Care, an update based on trial evidence and consensus about finerenone, SGLT2 inhibitors, and eGFR.

Related Keywords

United States , Americans , American , Roberta Gabbay , , Practice Committee , National Kidney Foundation , American Society Of Nephrology Task , American College Of Cardiology , American Diabetes Association , Kowa Company , Scientific Sessions , Medical Care , American Society , Nephrology Task Force , Living Standards , Risk Management , Kidney Disease , American College , Living Standards Update , Chronic Kidney Disease Epidemiology Collaboration , African Americans , Subjects With Type , Diabetic Kidney Disease , Clinical Diagnosis , Outcome Trial , Functional Status , Fraction Heart Failure , Reduce Cardiovascular Outcomes , Reducing Triglycerides , Diabetes Mellitus Type 2 , Iabetes Mellitus Type Ii , Type 2 Diabetes , Diabetes Mellitus , Chronic Renal Failure , Hronic Kidney Failure , Hronic Kidney Disease Ckd , Chronic Kidney Disease , Kd , Renal Failure , Enal Insufficiency , Idney Insufficiency , Kidney Failure , Acute Kidney Injury Aki , Acute Kidney Injury , Eski , Heart Failure , Endocrinology , Ndocrine System , Renal Disease , Kidney ,